Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · IEX Real-Time Price · USD
21.48
-0.04 (-0.19%)
Mar 30, 2023, 1:09 PM EDT - Market open
-0.19%
Market Cap 2.28B
Revenue (ttm) 35.38M
Net Income (ttm) -248.71M
Shares Out 106.17M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 506,527
Open 21.61
Previous Close 21.52
Day's Range 21.11 - 22.19
52-Week Range 14.08 - 31.37
Beta 1.49
Analysts Buy
Price Target 32.51 (+51.35%)
Earnings Date May 8, 2023

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2020
Employees 239
Stock Exchange NASDAQ
Ticker Symbol RVMD
Full Company Profile

Financial Performance

In 2022, RVMD's revenue was $35.38 million, an increase of 20.38% compared to the previous year's $29.39 million. Losses were -$248.71 million, 32.9% more than in 2021.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is $32.51, which is an increase of 51.35% from the latest price.

Price Target
$32.51
(51.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Underwriters' full exercise of option brings gross proceeds to $345.0 million Underwriters' full exercise of option brings gross proceeds to $345.0 million

3 weeks ago - GlobeNewsWire

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

3 weeks ago - GlobeNewsWire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today anno...

1 month ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s...

1 month ago - Zacks Investment Research

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation

1 month ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

1 month ago - GlobeNewsWire

Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice

Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

2 months ago - GlobeNewsWire

Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?

Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st...

2 months ago - Zacks Investment Research

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Ke...

3 months ago - Business Wire

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi's Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combinatio...

4 months ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

5 months ago - Zacks Investment Research

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

5 months ago - GlobeNewsWire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor

KRAS G12C (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRAS G12C mutation

6 months ago - GlobeNewsWire

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel

7 months ago - GlobeNewsWire

Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

7 months ago - Zacks Investment Research

Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is quest...

8 months ago - Zacks Investment Research

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock...

8 months ago - Zacks Investment Research

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

First two RAS(ON) Inhibitor drug candidates advance into clinical development

8 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

8 months ago - GlobeNewsWire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Underwriters' full exercise of option brings gross proceeds to $264.5 million Underwriters' full exercise of option brings gross proceeds to $264.5 million

8 months ago - GlobeNewsWire

Revolution Medicines Stock Is Getting Hammered: Here's Why

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares ...

9 months ago - Benzinga

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

9 months ago - GlobeNewsWire

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

Board composition evolves as company's development pipeline matures Board composition evolves as company's development pipeline matures

9 months ago - GlobeNewsWire

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRAS G12 mutations

9 months ago - GlobeNewsWire